Alterity Therapeutics, Ltd. announced the award of a grant from The Michael J. Fox Foundation for Parkinson’s Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson’s disease based on imaging of brain iron.
[Alterity Therapeutics, Ltd.]
6807162
{6807162:nan}
apa
50
1
158909
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
